- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00684996
Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer
A Phase I and a Randomized Phase II Study of Maximal Angiogenic Blockade in Advanced Renal Carcinoma: Bevacizumab (NSC-704865) With or Without MEDI-522 (NSC-719850)
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
PRIMARY OBJECTIVES:
I. To assess the appropriate dose of bevacizumab when administered with humanized monoclonal antibody MEDI-522 in patients with unresectable or metastatic renal cell carcinoma previously treated with sunitinib malate or sorafenib tosylate. (Phase I) II. To compare the progression-free survival of these patients treated with bevacizumab with versus without humanized monoclonal antibody MEDI-522. (Phase II) III. To evaluate the qualitative and quantitative toxicities of bevacizumab and humanized monoclonal antibody MEDI-522 in these patients. (Phase II) IV. To estimate overall survival and RECIST response rate (i.e., confirmed and unconfirmed, complete and partial responses) in both treatment arms. (Phase II)
OUTLINE: This is a multicenter, phase I, dose-escalation study of bevacizumab followed by a randomized phase II study.
PHASE I: Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and humanized monoclonal antibody MEDI-522 IV on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity until the recommended phase II dose (RPTD) of bevacizumab is determined.
PHASE II: Patients are stratified according to the number of prior treatment regimens for renal cell carcinoma (1 vs 2) and whether there is a clear cell component (yes vs no). Patients are randomized to 1 of 2 treatment arms:
ARM I: Patients receive bevacizumab (10 mg/kg) IV over 30-90 minutes on days 1 and 15.
ARM II: Patients receive bevacizumab IV as in arm I at the RPTD determined in phase I, and humanized monoclonal antibody MEDI-522 (8 mg/kg) IV over 30 minutes on days 1, 8, 15, and 22.
In both arms, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study therapy, patients are followed periodically for up to 3 years.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
California
-
Marysville, California, Forente stater, 95901
- Fremont - Rideout Cancer Center
-
Sacramento, California, Forente stater, 95817
- University of California at Davis Cancer Center
-
-
Michigan
-
Ann Arbor, Michigan, Forente stater, 48109
- University of Michigan
-
-
North Carolina
-
Charlotte, North Carolina, Forente stater, 28204
- Novant Health Presbyterian Medical Center
-
-
Oregon
-
Portland, Oregon, Forente stater, 97239
- SWOG
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
- Voksen
- Eldre voksen
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Criteria:
- Histologically or cytologically confirmed renal cell carcinoma
- Metastatic or unresectable disease
- Must have received prior sunitinib malate or sorafenib tosylate for metastatic or unresectable disease
- Measurable disease
- No soft tissue disease that has been irradiated within the past 2 months
- More than 6 months since prior and no concurrent treated or untreated brain metastases
- Stable, treated brain metastases allowed provided they remained stable for more than 6 months
- Patients with clinical evidence of brain metastases must have a negative brain CT or MRI scan for metastatic disease
- Zubrod performance status 0-1
- Urine protein:creatinine ratio =< 0.5 OR urine protein < 1,000 mg by 24-hour collection
- Not be pregnant or nursing
- Fertile patients must use effective contraception during and for at least 6 months after completion of study therapy
- No serious or non-healing wound, ulcer, or bone fracture
- No clinically relevant bleeding diathesis or coagulopathy
- No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days
- No significant traumatic injury within the past 28 days
- No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
- No other prior malignancy, except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for 5 years
- No New York Heart Association class II-IV congestive heart failure
- No unstable symptomatic arrhythmia requiring medication
- Chronic, controlled arrhythmias (e.g., atrial fibrillation or paroxysmal supraventricular tachycardia) allowed
- None of the following cardiovascular conditions within the past 6 months: Arterial thrombosis, Unstable angina, Myocardial infarction, Cerebrovascular accident
- Must have controlled blood pressure, defined as systolic blood pressure (BP) =< 160 mm Hg and/or diastolic BP =< 90 mm Hg
- More than 7 days since prior core biopsy
- At least 14 days since completion of prior therapy and recovered
- At least 28 days since prior radiotherapy and recovered
- No prior radiotherapy to >= 25% of bone marrow
- No more than two prior systemic regimens for renal cell carcinoma (including adjuvant treatment)
- No prior bevacizumab or humanized monoclonal antibody MEDI-522
- No major surgical procedure or open biopsy within the past 28 days
- No concurrent need for a major surgical procedure
- Concurrent full-dose anticoagulation with warfarin allowed provided INR is between 2-3
- Concurrent low molecular weight heparin allowed
- No clinically significant vascular disease (e.g., aortic aneurysm or history of aortic dissection)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Aktiv komparator: Phase II Arm I
Patients receive bevacizumab (10mg/kg) IV over 30-90 minutes on days 1 and 15.
|
Gitt IV
Andre navn:
|
Aktiv komparator: Phase II Arm II
Patients receive bevacizumab IV as in arm I at the RPTD determined in phase I, and humanized monoclonal antibody MEDI-522 (8mg/kg) IV over 30 minutes on days 1, 8, 15, and 22.
|
Gitt IV
Andre navn:
Given IV
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Maximum Tolerated Dose of Bevacizumab , Based on Incidence of Dose-limiting Toxicity (DLT) Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (Phase I)
Tidsramme: Up to 8 weeks
|
Up to 8 weeks
|
|
Progression-free Survival (Phase II)
Tidsramme: From date of registration to date of first observation of progressive disease, systemic deterioration, or death due to any cause, assessed up to 3 years
|
Measured from date of registration to date of first observation of progressive disease, symptomatic deterioration or death due to any cause.
Patients last known to be alive and progression-free are censored at date of last contact.
|
From date of registration to date of first observation of progressive disease, systemic deterioration, or death due to any cause, assessed up to 3 years
|
Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug, Graded According to NCI CTCAE Version 3.0 (Phase II)
Tidsramme: Up to 3 years
|
Adverse Events (AEs) are reported by the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.
For each patient, worst grade of each event type is reported.
Grade 3 = Severe, Grade 4 = Life-threatening, Grade 5 = Fatal.
|
Up to 3 years
|
Overall Survival (Phase II)
Tidsramme: From date of registration to date of death due to any cause, assessed up to 3 years
|
Measure from date of registration to date of death due to any cause.
Patients last known to be alive are censored at date of last contact.
|
From date of registration to date of death due to any cause, assessed up to 3 years
|
Response Rate According to Response Evaluation Criteria in Solid Tumors (RECIST), Including Confirmed and Unconfirmed Complete and Partial Responses (Phase II)
Tidsramme: Up to 3 years
|
Complete Response (CR) is a complete disappearance of all measurable and non-measurable disease.
No new lesions.
No disease related symptoms.
Partial Response (PR) applies only to patients with at least one measurable lesion.
Greater than or equal to 30% decrease under baseline of the sum of longest diameters of all target measurable lesions.
No unequivocal progression of nonmeasurable disease.
No new lesions.
|
Up to 3 years
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug
Tidsramme: Patients were assessed for the first 8 weeks for dose-limiting toxicities, then assessed for adverse events after every cycle (1 cycle = 28 days) of protocol treatment, up to 3 years
|
Adverse Events (AEs) are reported by the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.
For each patient, worst grade of each event type is reported.
Grade 3 = Severe, Grade 4 = Life-threatening, Grade 5 = Fatal.
|
Patients were assessed for the first 8 weeks for dose-limiting toxicities, then assessed for adverse events after every cycle (1 cycle = 28 days) of protocol treatment, up to 3 years
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Neoplasmer etter histologisk type
- Neoplasmer
- Urologiske neoplasmer
- Urogenitale neoplasmer
- Neoplasmer etter nettsted
- Nyresykdommer
- Urologiske sykdommer
- Adenokarsinom
- Neoplasmer, kjertel og epitel
- Nyre-neoplasmer
- Karsinom, nyrecelle
- Karsinom
- Fysiologiske effekter av legemidler
- Antineoplastiske midler
- Immunologiske faktorer
- Angiogenese-hemmere
- Angiogenesemodulerende midler
- Vekststoffer
- Veksthemmere
- Antistoffer
- Immunoglobuliner
- Bevacizumab
- Antistoffer, monoklonale
- Antineoplastiske midler, immunologiske
Andre studie-ID-numre
- NCI-2009-01099 (Registeridentifikator: CTRP (Clinical Trial Reporting Program))
- U10CA032102 (U.S. NIH-stipend/kontrakt)
- CDR0000596555
- S0717 (Annen identifikator: CTEP)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Nyrecellekarsinom
-
Debiopharm International SARekrutteringPankreas duktal adenokarsinom (PDAC) | Kolorektal kreft (CRC) | Clear Cell Renal Cell Cancer (ccRCC)Frankrike, Australia
-
University of Michigan Rogel Cancer CenterFullførtNyrecellekarsinomForente stater
-
Universitaire Ziekenhuizen KU LeuvenFullførtForekomst av utvidet renal clearance | Risikofaktorer for økt renal clearanceBelgia
-
Second Affiliated Hospital of Guangzhou Medical...Hunan Zhaotai Yongren Medical Innovation Co. Ltd.RekrutteringAnti-kreft celle immunterapi | T Cell og NK CellKina
-
Andrew B AdamsBristol-Myers SquibbFullført
-
University Health Network, TorontoFullførtGlomerulær filtreringshastighet | Renal blodstrømCanada
-
Oregon Health and Science UniversityFullført
-
Peking University People's HospitalUkjentNatural Killer Cell Medited ImmunitetKina
-
Center for International Blood and Marrow Transplant...Cellular Dynamics International, Inc. - A FUJIFILM CompanyAvsluttetiPS Cell Manufacturing and Banking
-
Erling Bjerregaard PedersenUniversity of AarhusUkjentRenal rørtransportDanmark
Kliniske studier på bevacizumab
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeTilbakevendende egglederkarsinom | Tilbakevendende ovariekarsinom | Tilbakevendende primært peritonealt karsinom | Klarcellet ovariecystadenokarsinom | Endometrioid adenokarsinom på eggstokkene | Serøst cystadenokarsinom på eggstokkene | Endometrie klarcellet adenokarsinom | Endometrial serøst adenokarsinom og andre forholdForente stater
-
National Cancer Institute (NCI)FullførtCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Livmorhalsplateepitelkarsinom, ikke spesifisert på annen måte | Stage IVA Livmorhalskreft AJCC v6 og v7 | Tilbakevendende livmorhalskreft | Stadium IV Livmorhalskreft AJCC v6 og v7 | Stadium IVB Livmorhalskreft AJCC v6 og v7Forente stater
-
National Cancer Institute (NCI)NRG OncologyFullførtBevacizumab med eller uten trebananib ved behandling av pasienter med tilbakevendende hjernesvulsterGlioblastom | Gliosarkom | Tilbakevendende glioblastom | Oligodendrogliom | Kjempecelleglioblastom | Tilbakevendende hjerneneoplasmaForente stater, Canada
-
M.D. Anderson Cancer CenterRekrutteringStage IB hepatocellulært karsinom AJCC v8 | Stage II hepatocellulært karsinom AJCC v8 | Resektabelt hepatocellulært karsinom | Stage I hepatocellulært karsinom AJCC v8 | Stage IA hepatocellulært karsinom AJCC v8Forente stater
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeStage IV kutant melanom AJCC v6 og v7 | Stage IIIC kutant melanom AJCC v7 | Uopererbart melanomForente stater
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RekrutteringTilbakevendende egglederkarsinom | Tilbakevendende ovariekarsinom | Tilbakevendende primært peritonealt karsinom | Endometrioid adenokarsinom på eggstokkene | Klarcellet adenokarsinom i eggstokkene | Klarcellet adenokarsinom i egglederen | Endometrioid adenokarsinom i egglederen | Serøst adenokarsinom... og andre forholdForente stater
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeEndometrioid adenokarsinom på eggstokkene | Primært peritonealt høygradig serøst adenokarsinom | Endometrioid adenokarsinom i egglederen | Platina-resistent egglederkarsinom | Platina-resistent primært peritonealt karsinom | Ovarial høygradig serøst adenokarsinom | Platina-resistent ovariekarsinom | Eggleder...Forente stater, Canada
-
City of Hope Medical CenterNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeMetastatisk lunge ikke-småcellet karsinom | Stage IVA lungekreft AJCC v8 | Stage IVB lungekreft AJCC v8 | Stadium III lungekreft AJCC v8 | Stadium IV lungekreft AJCC v8 | Stadium IIIA lungekreft AJCC v8 | Stadium IIIB lungekreft AJCC v8 | Stadium IIIC lungekreft AJCC v8 | Lokalt avansert ikke-småcellet... og andre forholdForente stater
-
Mayo ClinicNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeOndartet fast neoplasma | Endometrioid adenokarsinom på eggstokkene | Ovarialt udifferensiert karsinom | Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Ondartet peritoneal neoplasma | Endometrie klarcellet adenokarsinom | Endometrial Endometrioid Adenocarcinoma | Endometrie blandet celle adenokarsinom og andre forholdForente stater
-
Northwestern UniversityNational Cancer Institute (NCI); Ipsen BiopharmaceuticalsFullførtTilbakevendende egglederkarsinom | Tilbakevendende ovariekarsinom | Tilbakevendende primært peritonealt karsinom | Platina-resistent egglederkarsinom | Platina-resistent primært peritonealt karsinom | Platina-resistent ovariekarsinom | Ildfast ovariekarsinom | Ildfast egglederkarsinom | Refraktært primært...Forente stater